Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All nigella sativa studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchNigella SativaNigella Sativa (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Symp. case, any symptom 34% Improvement Relative Risk Symp. case, fever 97% Symp. case, chest pain 66% Symp. case, loss of taste/.. 62% Symp. case, muscle ache 26% Symp. case, chills -6% Symp. case, cough 79% Symp. case, headache 76% Symp. case, vomiting 98% Nigella Sativa  Daneshfard et al.  Prophylaxis  RCT Is prophylaxis with nigella sativa + olea europaea oil beneficial for COVID-19? RCT 173 patients in Iran (June 2021 - May 2022) Fewer symptomatic cases with nigella sativa + olea europaea oil (p=0.0061) c19early.org Daneshfard et al., Phytotherapy Research, Jul 2023 Favors nigella sativa Favors control

Effect of Sinamaz nasal drop on asymptomatic family members of COVID 19 patients: An open-label randomized controlled trial

Daneshfard et al., Phytotherapy Research, doi:10.1002/ptr.7915, IRCT20210515051305N1
Jul 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
11th treatment shown to reduce risk in January 2021
 
*, now known with p = 0.00016 from 14 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
RCT 173 family members of COVID-19 patients, showing lower incidence of COVID-19 symptoms with nasal drops containing nigella sativa oil and olea europaea oil. One drop in each nostril twice daily for 7 days.
Targeted administration to the respiratory tract provides treatment directly to the typical source of initial SARS-CoV-2 infection and replication, and allows for rapid onset of action, higher local drug concentration, and reduced systemic side effects.
risk of symptomatic case, 34.1% lower, RR 0.66, p = 0.006, treatment 37 of 89 (41.6%), control 53 of 84 (63.1%), NNT 4.6, any symptom.
risk of symptomatic case, 97.3% lower, RR 0.03, p < 0.001, treatment 1 of 89 (1.1%), control 35 of 84 (41.7%), NNT 2.5, fever.
risk of symptomatic case, 65.7% lower, RR 0.34, p = 0.06, treatment 4 of 89 (4.5%), control 11 of 84 (13.1%), NNT 12, chest pain.
risk of symptomatic case, 62.2% lower, RR 0.38, p = 0.10, treatment 4 of 89 (4.5%), control 10 of 84 (11.9%), NNT 13, loss of taste/smell.
risk of symptomatic case, 26.0% lower, RR 0.74, p = 0.16, treatment 29 of 89 (32.6%), control 37 of 84 (44.0%), NNT 8.7, muscle ache.
risk of symptomatic case, 6.2% higher, RR 1.06, p = 1.00, treatment 9 of 89 (10.1%), control 8 of 84 (9.5%), chills.
risk of symptomatic case, 79.0% lower, RR 0.21, p = 0.001, treatment 4 of 89 (4.5%), control 18 of 84 (21.4%), NNT 5.9, cough.
risk of symptomatic case, 76.4% lower, RR 0.24, p < 0.001, treatment 5 of 89 (5.6%), control 20 of 84 (23.8%), NNT 5.5, headache.
risk of symptomatic case, 98.1% lower, RR 0.02, p < 0.001, treatment 0 of 89 (0.0%), control 25 of 84 (29.8%), NNT 3.4, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), vomiting.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Daneshfard et al., 16 Jul 2023, Randomized Controlled Trial, Iran, peer-reviewed, mean age 39.5 (treatment) 34.0 (control), 16 authors, study period 16 June, 2021 - 22 May, 2022, this trial uses multiple treatments in the treatment arm (combined with olea europaea oil) - results of individual treatments may vary, trial IRCT20210515051305N1.
This PaperNigella SativaAll
{ 'DOI': '10.1002/ptr.7915', 'ISSN': ['0951-418X', '1099-1573'], 'URL': 'http://dx.doi.org/10.1002/ptr.7915', 'alternative-id': ['10.1002/ptr.7915'], 'assertion': [ { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Received', 'name': 'received', 'order': 0, 'value': '2022-12-07'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Accepted', 'name': 'accepted', 'order': 1, 'value': '2023-05-27'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Published', 'name': 'published', 'order': 2, 'value': '2023-07-16'}], 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-6729-9113', 'affiliation': [ { 'name': 'Chronic Respiratory Diseases Research Center, National Research ' 'Institute of Tuberculosis and Lung Diseases (NRITLD) Shahid ' 'Beheshti University of Medical Sciences Tehran Iran'}, { 'name': 'Traditional Medicine Clinical Trial Research Center Shahed ' 'University Tehran Iran'}, { 'name': 'Persian Medicine Network (PMN) Universal Scientific Education ' 'and Research Network (USERN) Tehran Iran'}], 'authenticated-orcid': False, 'family': 'Daneshfard', 'given': 'Babak', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'Department of Scientific Research Kian Asa Center for Preventive ' 'Medicine (SBMU Supervised Area) &amp; Scientific Authority ' 'Center for Countering Biological Treats Tehran Iran'}], 'family': 'Aghanouri', 'given': 'Reza', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Biostatistics, Faculty of Medical Sciences Tarbiat ' 'Modares University Tehran Iran'}], 'family': 'Kazemnejad', 'given': 'Anoshiravan', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-5998-7303', 'affiliation': [ { 'name': 'School of Life Sciences University of Technology Sydney Ultimo ' 'New South Wales Australia'}, { 'name': 'Ingham Institute for Applied Medical Research Liverpool New ' 'South Wales Australia'}], 'authenticated-orcid': False, 'family': 'Fatima Shad', 'given': 'Kaneez', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Ingham Institute for Applied Medical Research Liverpool New ' 'South Wales Australia'}, { 'name': 'Department of Neurophysiology Liverpool Hospital Liverpool New ' 'South Wales Australia'}], 'family': 'Cordato', 'given': 'Dennis', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'School of Life Sciences University of Technology Sydney Ultimo ' 'New South Wales Australia'}, { 'name': 'Ingham Institute for Applied Medical Research Liverpool New ' 'South Wales Australia'}], 'family': 'Soubra', 'given': 'Wissam', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Traditional Medicine Clinical Trial Research Center Shahed ' 'University Tehran Iran'}, { 'name': 'Department of Traditional Persian Medicine, School of Medicine ' 'Shahed University Tehran Iran'}], 'family': 'Bahaeddin', 'given': 'Zahra', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Molecular Biology Research Center, Systems Biology and ' 'Poisonings Institute Bagiyatallah University of Medical Science ' 'Tehran Iran'}], 'family': 'Hosseini', 'given': 'Seyed Mohammad Javad', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Virology, Faculty of Medical Sciences Tarbiat ' 'Modares University Tehran Iran'}], 'family': 'Ravanshad', 'given': 'Mehrdad', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-6607-0640', 'affiliation': [ { 'name': 'Traditional Medicine Clinical Trial Research Center Shahed ' 'University Tehran Iran'}, { 'name': 'Department of Traditional Persian Medicine, School of Medicine ' 'Shahed University Tehran Iran'}], 'authenticated-orcid': False, 'family': 'Alijaniha', 'given': 'Fatemeh', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'School of Pharmacy Shahid Beheshti University of Medical ' 'Sciences Tehran Iran'}], 'family': 'Kamalinejad', 'given': 'Mohammad', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Traditional Medicine Clinical Trial Research Center Shahed ' 'University Tehran Iran'}], 'family': 'Jafari Hajati', 'given': 'Razieh', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Traditional Medicine Clinical Trial Research Center Shahed ' 'University Tehran Iran'}], 'family': 'Rafie Tari', 'given': 'Amir', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'School of Traditional Medicine Shahid Beheshti University of ' 'Medical Sciences Tehran Iran'}], 'family': 'Ghaffari', 'given': 'Farzaneh', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0001-9239-768X', 'affiliation': [ { 'name': 'Traditional Medicine Clinical Trial Research Center Shahed ' 'University Tehran Iran'}, { 'name': 'Department of Traditional Persian Medicine, School of Medicine ' 'Shahed University Tehran Iran'}, { 'name': 'Hikmat, Islamic and Traditional Medicine Department The Academy ' 'of Medical Sciences Tehran Iran'}], 'authenticated-orcid': False, 'family': 'Naseri', 'given': 'Mohsen', 'sequence': 'additional'}], 'container-title': 'Phytotherapy Research', 'container-title-short': 'Phytotherapy Research', 'content-domain': {'crossmark-restriction': True, 'domain': ['onlinelibrary.wiley.com']}, 'created': {'date-parts': [[2023, 7, 17]], 'date-time': '2023-07-17T04:44:09Z', 'timestamp': 1689569049000}, 'deposited': { 'date-parts': [[2024, 4, 9]], 'date-time': '2024-04-09T12:12:22Z', 'timestamp': 1712664742000}, 'indexed': {'date-parts': [[2024, 4, 9]], 'date-time': '2024-04-09T12:40:29Z', 'timestamp': 1712666429086}, 'is-referenced-by-count': 0, 'issue': '4', 'issued': {'date-parts': [[2023, 7, 16]]}, 'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2024, 4]]}}, 'language': 'en', 'license': [ { 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2023, 7, 16]], 'date-time': '2023-07-16T00:00:00Z', 'timestamp': 1689465600000}}], 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/ptr.7915', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '311', 'original-title': [], 'page': '1727-1730', 'prefix': '10.1002', 'published': {'date-parts': [[2023, 7, 16]]}, 'published-online': {'date-parts': [[2023, 7, 16]]}, 'published-print': {'date-parts': [[2024, 4]]}, 'publisher': 'Wiley', 'reference': [ { 'DOI': '10.3109/14764172.2014.968583', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_2_2_1'}, { 'article-title': 'Prolegomena to a true integrative medical paradigm', 'author': 'Daneshfard B.', 'first-page': '50', 'issue': '2', 'journal-title': 'Alternative Therapies in Health and Medicine', 'key': 'e_1_2_2_3_1', 'volume': '25', 'year': '2019'}, {'DOI': '10.1111/1440-1681.13553', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_2_4_1'}, {'DOI': '10.1002/ptr.6895', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_2_5_1'}, { 'article-title': 'SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19', 'author': 'Kreuzberger N.', 'first-page': 'D013825', 'issue': '9', 'journal-title': 'Cochrane Database of Systematic Reviews', 'key': 'e_1_2_2_6_1', 'volume': '9', 'year': '2021'}, {'DOI': '10.1073/pnas.2109229118', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_2_7_1'}, {'DOI': '10.1016/j.cmi.2020.10.036', 'doi-asserted-by': 'publisher', 'key': 'e_1_2_2_8_1'}, { 'key': 'e_1_2_2_9_1', 'unstructured': 'WHO. (n.d.).WHO (COVID‐19) Homepage. Retrieved ' 'fromhttps://covid19.who.int'}], 'reference-count': 8, 'references-count': 8, 'relation': {}, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1002/ptr.7915'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Pharmacology'], 'subtitle': [], 'title': 'Effect of Sinamaz nasal drop on asymptomatic family members of <scp>COVID</scp> 19 patients: An ' 'open‐label randomized controlled trial', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'volume': '38'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit